Schizophrenia: Overview and Dopamine Dysfunction
Abstract
Article AbstractSchizophrenia is a chronic, often disabling illness that affects approximately 24 million people worldwide. Unfortunately, while the majority of first-episode schizophrenia patients respond well to initial antipsychotic treatment, less than 1 in 5 will maintain recovery over 2 to 5 years, and most will experience at least 1 relapse. Dopamine dysfunction helps to explain the positive symptoms experienced by patients with schizophrenia, and targeting these pathways has made current antipsychotics effective treatments for this condition. However, these agents primarily manage the positive symptoms of the disorder, while negative and cognitive symptoms can persist. More treatments are needed that comprehensively address all presentations of the disorder.From the Division of Translational Imaging, Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York. This CME activity is expired. For more CME activities, visit cme.psychiatrist.com. Find more articles on this and other psychiatry and CNS topics: The Journal of Clinical Psychiatry The Primary Care Companion for CNS Disorders
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prairie voles show strong OXTR expression in MLR regions, a conserved reward-processing network implicated in depression, addiction, and schizophrenia.
“Prairie voles strongly express OXTR in regions of the MLR, a conserved neural network (75) involved in reward processing and implicated in numerous human psychiatric disorders including depression (76), addiction (77), and schizophrenia (78).”
From Variation in the Oxytocin Receptor Gene Predicts Brain Region–Specific Expression and Social Attachment (2016) · cites this paper as [77]
Cited by
Sorted by citations
Dauwan, M., Begemann, M. J. H., Heringa, S. M., & Sommer, I. E. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv164 · Cited by 393 · see citing works
Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review
Trépanier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N., & Bazinet, R. P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.90 · Cited by 360 · see citing works
King, L. B., Walum, H., Inoue, K., Eyrich, N. W., & Young, L. J. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.008 · Cited by 191 · see citing works
“Prairie voles strongly express OXTR in regions of the MLR, a conserved neural network (74) involved in reward processing and implicated in numerous human psychiatric disorders, including depression (75), addiction (76), and schizophrenia (77).”
Modeling psychiatric disorders with patient-derived iPSCs
Wen, Z., Christian, K. M., Song, H., & Ming, G.-L. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.003 · Cited by 84 · see citing works
Striatal dopamine, reward, and decision making in schizophrenia
Deserno, L., Schlagenhauf, F., & Heinz, A. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/ldeserno · Cited by 58 · see citing works
A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence
Alexander, P. D., Gicas, K. M., Willi, T. S., Kim, C. N., Boyeva, V., Procyshyn, R. M., Smith, G. N., Thornton, A. E., Panenka, W. J., Jones, A. A., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4551-7 · Cited by 29 · see citing works
Yin, J., Sun, Y., Zhu, Y., Alifujiang, H., Wang, Y., An, S., Huang, H., Fu, X., Deng, H., & Chen, Y. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.103959 · Cited by 15 · see citing works
- Authors
- Abi-Dargham, A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-11-24
- Volume
- 75
- Issue
- 11
- Pages
- e31-e31
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1986619545
- Cited by
- 128
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 9 · 2017: 52 · 2016: 14 · 2015: 8 · 2013: 1 · 2012: 2
- FWCI
- 18.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, first-episode schizophrenia, antipsychotic drugs, relapse, dopaminergic dysfunction, positive symptoms, negative symptoms, cognitive symptoms, treatment-resistant schizophrenia
- MeSH terms
- Dopamine, Humans, Schizophrenia, Cerebrum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
